Clinical Trial Update: Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial results for mifepristone (CORLUX) in endogenous Cushing's syndrome have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease
• Cushing Syndrome

Drugs mentioned

• CORLUX (mifepristone)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Cushing's Disease, Cushing's Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2013-11-20